Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>United Therapeutics Corporation reported total revenue of $782 million for the first quarter of 2026, reflecting typical seasonal trends, severe winter weather, and pharmacy operational challenges that temporarily slowed patient starts, particularly in February.</li><li>Despite these headwinds, management anticipates a return to sequential growth in the near term.</li><li>Tyvaso, the company’s nebulized inhaled prostacyclin, generated $458 million, with the newer Tyvaso DPI format contributing 9% year-over-year growth driven by increasing patient demand.</li></ul>

United Therapeutics Corporation reported total revenue of $782 million for the first quarter of 2026, reflecting typical seasonal trends, severe winter weather, and pharmacy operational challenges that temporarily slowed patient starts, particularly in February.Despite these headwinds, management anticipates a return to sequential growth in the near term.Tyvaso, the company’s nebulized inhaled prostacyclin, generated $458 million, with the newer Tyvaso DPI format contributing 9% year-over-year growth driven by increasing patient demand.

United Therapeutics’ Ralinepag Breakthrough: Can PAH Patient Numbers Double?

<ul><li>United Therapeutics has moved sharply higher after fresh Phase 3 data strengthened the case for Tyvaso in idiopathic pulmonary fibrosis, or IPF, but the bigger story may not be the single trial result itself.</li><li>What stands out is that Tyvaso increasingly looks less like one successful pulmonary hypertension medicine and more like a franchise that keeps expanding through new indications, new delivery formats, and higher patient utility.</li><li>The current business is already substantial, with Tyvaso generating $1.88 billion in 2025 sales and remaining the company’s main commercial engine.</li></ul>

United Therapeutics has moved sharply higher after fresh Phase 3 data strengthened the case for Tyvaso in idiopathic pulmonary fibrosis, or IPF, but the bigger story may not be the single trial result itself.What stands out is that Tyvaso increasingly looks less like one successful pulmonary hypertension medicine and more like a franchise that keeps expanding through new indications, new delivery formats, and higher patient utility.The current business is already substantial, with Tyvaso generating $1.88 billion in 2025 sales and remaining the company’s main commercial engine.

United Therapeutics: The $2 Billion Drug That Could Quietly Become A $10 Billion Franchise!

<ul><li>United Therapeutics Corporation's latest quarterly update presents a mixed but overall solid performance, highlighting both achievements and challenges.</li><li>The company reported record-breaking revenue, exceeding $3 billion for the first time, driven by strong sales growth in key products like Tyvaso and Orenitram.</li><li>For the fourth quarter, United Therapeutics saw a 7% increase in total revenue compared to the same period last year, reaching $790 million.</li></ul>

United Therapeutics Corporation's latest quarterly update presents a mixed but overall solid performance, highlighting both achievements and challenges.The company reported record-breaking revenue, exceeding $3 billion for the first time, driven by strong sales growth in key products like Tyvaso and Orenitram.For the fourth quarter, United Therapeutics saw a 7% increase in total revenue compared to the same period last year, reaching $790 million.

United Therapeutics Unveils Game-Changing Soft Mist Inhaler That Could Transform Pulmonary Hypertension Treatment!

<ul><li>United Therapeutics Corporation's third-quarter results for 2025 demonstrate both the company's operational strengths and challenges.</li><li>United Therapeutics reported record revenues of $800 million, up 7% from the same period in 2024, largely driven by increased demand for Tyvaso and Orenitram, key therapies in their portfolio addressing pulmonary hypertension (PH) and interstitial lung diseases.</li><li>This revenue growth is indicative of the effectiveness of their commercial strategies and market execution, underscoring the resilience of their business model despite increased competition.</li></ul>

United Therapeutics Corporation's third-quarter results for 2025 demonstrate both the company's operational strengths and challenges.United Therapeutics reported record revenues of $800 million, up 7% from the same period in 2024, largely driven by increased demand for Tyvaso and Orenitram, key therapies in their portfolio addressing pulmonary hypertension (PH) and interstitial lung diseases.This revenue growth is indicative of the effectiveness of their commercial strategies and market execution, underscoring the resilience of their business model despite increased competition.

United Therapeutics Eyes Billion-Dollar IPF Market—Can They Pull It Off?

<ul><li>United Therapeutics Corporation's second quarter 2025 results showcase a continuation of its strategic momentum, marked by 12 consecutive quarters of double-digit year-over-year revenue growth.</li><li>Total quarterly revenue reached a record $799 million, representing 12% growth from the same period in 2024.</li><li>The Tyvaso franchise, notably Tyvaso DPI, was a standout performer, achieving $315 million in total revenue, a 22% increase.</li></ul>

United Therapeutics Corporation's second quarter 2025 results showcase a continuation of its strategic momentum, marked by 12 consecutive quarters of double-digit year-over-year revenue growth.Total quarterly revenue reached a record $799 million, representing 12% growth from the same period in 2024.The Tyvaso franchise, notably Tyvaso DPI, was a standout performer, achieving $315 million in total revenue, a 22% increase.

United Therapeutics: The Top 6 Influences on Its Performance for 2025 & The Future!

United States

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease.  The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

United Therapeutics (UTHR US)

United Therapeutics’ Ralinepag Breakthrough: Can PAH Patient Numbers Double?

United Therapeutics Corporation reported total revenue of $782 million for the first quarter of 2026, reflecting typical seasonal trends, severe...

Baptista Research

United Therapeutics: The $2 Billion Drug That Could Quietly Become A $10 Billion Franchise!

United Therapeutics has moved sharply higher after fresh Phase 3 data strengthened the case for Tyvaso in idiopathic pulmonary fibrosis, or IPF,...

Baptista Research

United Therapeutics Unveils Game-Changing Soft Mist Inhaler That Could Transform Pulmonary Hypertension Treatment!

United Therapeutics Corporation's latest quarterly update presents a mixed but overall solid performance, highlighting both achievements and...

Baptista Research

United Therapeutics Eyes Billion-Dollar IPF Market—Can They Pull It Off?

United Therapeutics Corporation's third-quarter results for 2025 demonstrate both the company's operational strengths and challenges. United...

Baptista Research

United Therapeutics: The Top 6 Influences on Its Performance for 2025 & The Future!

United Therapeutics Corporation's second quarter 2025 results showcase a continuation of its strategic momentum, marked by 12 consecutive quarters...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)